Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

59 results about "Basal ganglia dysfunction" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Damage to the basal ganglia cells may cause problems controlling speech, movement, and posture. This combination of symptoms is called parkinsonism. A person with basal ganglia dysfunction may have difficulty starting, stopping, or sustaining movement.

Quinolinone PDE2 inhibitors

ActiveUS8680116B2BiocideNervous disorderHuntingtons choreaBasal ganglia dysfunction

The present invention is directed to quinolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Quinolinone PDE2 inhibitors

Quinolinone PDE2 inhibitors

Quinolinone PDE2 inhibitors

Owner:MERCK SHARP & DOHME LLC

Quinolinone PDE2 Inhibitors

ActiveUS20120115885A1Useful in therapyBiocideNervous disorderDiseaseBasal ganglia dysfunction

The present invention is directed to quinolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Quinolinone PDE2 Inhibitors

Quinolinone PDE2 Inhibitors

Quinolinone PDE2 Inhibitors

Owner:MERCK SHARP & DOHME LLC

Aryl aminopyridine pde10 inhibitors

InactiveUS20120196856A1BiocideNervous disorderBasal ganglia dysfunctionHuntingtons chorea

The present invention is directed to aryl aminopyridine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Aryl aminopyridine pde10 inhibitors

Aryl aminopyridine pde10 inhibitors

Aryl aminopyridine pde10 inhibitors

Owner:MERCK SHARP & DOHME CORP

Isoindoline pde10 inhibitors

InactiveUS20130203756A1BiocideNervous disorderDiseasePhosphodiesterase

The present invention is directed to isoindolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Isoindoline pde10 inhibitors

Isoindoline pde10 inhibitors

Isoindoline pde10 inhibitors

Owner:MERCK SHARP & DOHME CORP

Pyrazolopyrimidine PDE 10 inhibitors

ActiveUS20130137707A1BiocideOrganic active ingredientsBasal ganglia dysfunctionDisease

The present invention is directed to pyrazolopyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Pyrazolopyrimidine PDE 10 inhibitors

Pyrazolopyrimidine PDE 10 inhibitors

Pyrazolopyrimidine PDE 10 inhibitors

Owner:MERCK SHARP & DOHME LLC

Cyclobutyl benzimidazoles as PDE 10 inhibitors

ActiveUS20150307479A1Useful in therapyBiocideOrganic active ingredientsBasal ganglia dysfunctionPhosphodiesterase

The present invention is directed to substituted cyclobutyl benzimidazole compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Cyclobutyl benzimidazoles as PDE 10 inhibitors

Cyclobutyl benzimidazoles as PDE 10 inhibitors

Cyclobutyl benzimidazoles as PDE 10 inhibitors

Owner:MERCK SHARP & DOHME LLC

Alkoxy tetrahydro-pyridopyrimidine pde10 inhibitors

InactiveUS20120065211A1BiocideNervous disorderHuntingtons choreaPhosphodiesterase

The present invention is directed to alkoxy tetrahydro-pyridopyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Alkoxy tetrahydro-pyridopyrimidine pde10 inhibitors

Alkoxy tetrahydro-pyridopyrimidine pde10 inhibitors

Alkoxy tetrahydro-pyridopyrimidine pde10 inhibitors

Owner:MERCK SHARP & DOHME CORP

Alkoxy pyrimidine PDE10 inhibitors

ActiveUS8785467B2Organic active ingredientsBiocideBasal ganglia dysfunctionHuntingtons chorea

The present invention is directed to 2-alkoxy pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Alkoxy pyrimidine PDE10 inhibitors

Alkoxy pyrimidine PDE10 inhibitors

Alkoxy pyrimidine PDE10 inhibitors

Owner:MERCK SHARP & DOHME LLC

Aryloxmethyl cyclopropane derivatives as PDE10 inhibitors

ActiveUS8975261B2BiocideOrganic chemistryPhosphodiesteraseDisease

The present invention is directed to aryloxymethyl cyclopropane derivatives which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Aryloxmethyl cyclopropane derivatives as PDE10 inhibitors

Aryloxmethyl cyclopropane derivatives as PDE10 inhibitors

Aryloxmethyl cyclopropane derivatives as PDE10 inhibitors

Owner:MERCK SHARP & DOHME LLC

Triazolyl pyrimidinone compounds as PDE2 inhibitors

InactiveCN107530343AOrganic active ingredientsNervous disorderBasal ganglia dysfunctionHuntingtons chorea

The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Triazolyl pyrimidinone compounds as PDE2 inhibitors

Triazolyl pyrimidinone compounds as PDE2 inhibitors

Triazolyl pyrimidinone compounds as PDE2 inhibitors

Owner:MERCK & CO INC

Secondary alcohol substituted triazoles as pde10 inhibitors

ActiveUS20150284368A1BiocideOrganic active ingredientsHuntingtons choreaPhosphodiesterase

The present invention is directed to secondary alcohol substituted triazole compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Secondary alcohol substituted triazoles as pde10 inhibitors

Secondary alcohol substituted triazoles as pde10 inhibitors

Secondary alcohol substituted triazoles as pde10 inhibitors

Owner:MERCK SHARP & DOHME LLC

1,3 substituted azetidine pde10 inhibitors

ActiveUS20140256708A1BiocideOrganic active ingredientsPhosphodiesteraseHuntingtons chorea

The present invention is directed to substituted azetidinecompounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

1,3 substituted azetidine pde10 inhibitors

1,3 substituted azetidine pde10 inhibitors

1,3 substituted azetidine pde10 inhibitors

Owner:MERCK SHARP & DOHME LLC

Amino tetrahydro-pyridopyrimidine PDE10 inhibitors

InactiveUS8691827B2Organic active ingredientsBiocideBasal ganglia dysfunctionDisease

The present invention is directed to amino tetrahydro-pyridopyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Amino tetrahydro-pyridopyrimidine PDE10 inhibitors

Amino tetrahydro-pyridopyrimidine PDE10 inhibitors

Amino tetrahydro-pyridopyrimidine PDE10 inhibitors

Owner:MERCK SHARP & DOHME CORP

Bicyclic heterocyclic compounds as PDE2 inhibitors

ActiveUS10287293B2Nervous disorderOrganic chemistryPhosphodiesteraseHuntingtons chorea

The present invention is directed to dihydropyrazolopyrimidinone compounds of formulas (I) and (II) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Bicyclic heterocyclic compounds as PDE2 inhibitors

Bicyclic heterocyclic compounds as PDE2 inhibitors

Bicyclic heterocyclic compounds as PDE2 inhibitors

Owner:MERCK SHARP & DOHME LLC

Pyrazolopyrimidine pde9 inhibitors

ActiveUS20180354955A1Useful in therapyOrganic active ingredientsNervous disorderHuntingtons choreaPhosphodiesterase

The present invention is directed to pyrazolopyrimidine compounds which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Pyrazolopyrimidine pde9 inhibitors

Pyrazolopyrimidine pde9 inhibitors

Pyrazolopyrimidine pde9 inhibitors

Owner:MERCK SHARP & DOHME LLC

Substituted pyridone derivatives as PDE10 inhibitors

ActiveUS9273033B2Organic active ingredientsOrganic chemistryDiseasePhosphodiesterase

The present invention is directed to substituted pyridinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Substituted pyridone derivatives as PDE10 inhibitors

Substituted pyridone derivatives as PDE10 inhibitors

Substituted pyridone derivatives as PDE10 inhibitors

Owner:MERCK SHARP & DOHME LLC

Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors

ActiveUS20180148453A1Nervous disorderOrganic chemistryPhosphodiesteraseHuntingtons chorea

The present invention is directed to dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors

Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors

Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors

Owner:MERCK SHARP & DOHME LLC +1

Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors

ActiveUS20180162874A1Nervous disorderOrganic chemistryBasal ganglia dysfunctionHuntingtons chorea

The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Owner:MERCK SHARP & DOHME LLC

Substituted pyridone derivatives as PDE10 inhibitors

ActiveUS20150291561A1BiocideOrganic chemistryBasal ganglia dysfunctionDisease

The present invention is directed to substituted pyridinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Substituted pyridone derivatives as PDE10 inhibitors

Substituted pyridone derivatives as PDE10 inhibitors

Substituted pyridone derivatives as PDE10 inhibitors

Owner:MERCK SHARP & DOHME LLC

Phenyl-cyanoquinolinone PDE9 inhibitors

ActiveUS20180208557A1Nervous disorderOrganic chemistryDiseasePhosphodiesterase

The present invention is directed to phenylcyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Phenyl-cyanoquinolinone PDE9 inhibitors

Phenyl-cyanoquinolinone PDE9 inhibitors

Phenyl-cyanoquinolinone PDE9 inhibitors

Owner:MERCK SHARP & DOHME LLC

Aza-cyanoquinolinone pde9 inhibitors

ActiveUS20180214439A1Nervous disorderOrganic chemistryBasal ganglia dysfunctionDisease

The present invention is directed to azacyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Aza-cyanoquinolinone pde9 inhibitors

Aza-cyanoquinolinone pde9 inhibitors

Aza-cyanoquinolinone pde9 inhibitors

Owner:MERCK SHARP & DOHME LLC

Alkoxy tetrahydro-pyridopyrimidine PDE10 inhibitors

InactiveUS8492392B2BiocideNervous disorderDiseaseBasal ganglia dysfunction

The present invention is directed to alkoxy tetrahydro-pyridopyrimidine compounds of formula I, which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Alkoxy tetrahydro-pyridopyrimidine PDE10 inhibitors

Alkoxy tetrahydro-pyridopyrimidine PDE10 inhibitors

Alkoxy tetrahydro-pyridopyrimidine PDE10 inhibitors

Owner:MERCK SHARP & DOHME CORP

Triazolopyridinone pde10 inhibitors

ActiveUS20140343053A1BiocideNervous disorderDiseaseHuntingtons chorea

The present invention is directed to triazolopyridinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Triazolopyridinone pde10 inhibitors

Triazolopyridinone pde10 inhibitors

Triazolopyridinone pde10 inhibitors

Owner:MERCK SHARP & DOHME LLC

6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors

ActiveUS10160762B2Organic active ingredientsNervous disorderPhosphodiesteraseHuntingtons chorea

The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypo-function or basal ganglia dysfunction.

6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors

6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors

6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors

Owner:MERCK SHARP & DOHME LLC +1

Aryl aminopyridine PDE10 inhibitors

InactiveUS8349830B2BiocideNervous disorderBasal ganglia dysfunctionDisease

The present invention is directed to aryl aminopyridine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Aryl aminopyridine PDE10 inhibitors

Aryl aminopyridine PDE10 inhibitors

Aryl aminopyridine PDE10 inhibitors

Owner:MERCK SHARP & DOHME CORP

Pyrazolopyrimidine PDE 10 inhibitors

ActiveUS8957077B2BiocideOrganic active ingredientsPhosphodiesterase IHuntingtons chorea

The present invention is directed to pyrazolopyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Pyrazolopyrimidine PDE 10 inhibitors

Pyrazolopyrimidine PDE 10 inhibitors

Pyrazolopyrimidine PDE 10 inhibitors

Owner:MERCK SHARP & DOHME LLC

Heteroaryl-Pyrimidinone Compounds as PDE2 Inhibitors

ActiveUS20180280390A1Organic active ingredientsNervous disorderHuntingtons choreaBasal ganglia dysfunction

The present invention is directed to substituted pyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Heteroaryl-Pyrimidinone Compounds as PDE2 Inhibitors

Heteroaryl-Pyrimidinone Compounds as PDE2 Inhibitors

Heteroaryl-Pyrimidinone Compounds as PDE2 Inhibitors

Owner:MERCK SHARP & DOHME LLC

Pyrimidine PDE10 inhibitors

ActiveUS9062059B2Organic active ingredientsNervous disorderBasal ganglia dysfunctionPhosphodiesterase

The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Pyrimidine PDE10 inhibitors

Pyrimidine PDE10 inhibitors

Pyrimidine PDE10 inhibitors

Owner:MERCK SHARP & DOHME LLC

Substituted amino-triazolyl pde10 inhibitors

InactiveUS20130225583A1BiocideOrganic active ingredientsBasal ganglia dysfunctionHuntingtons chorea

The present invention is directed to substituted amino-triazolyl compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Substituted amino-triazolyl pde10 inhibitors

Substituted amino-triazolyl pde10 inhibitors

Substituted amino-triazolyl pde10 inhibitors

Owner:MERCK SHARP & DOHME CORP

Pyrazolyl pyrimidinone compounds as pde2 inhibitors

ActiveUS20180057480A1Organic chemistryHuntingtons choreaBasal ganglia dysfunction

The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Pyrazolyl pyrimidinone compounds as pde2 inhibitors

Pyrazolyl pyrimidinone compounds as pde2 inhibitors

Pyrazolyl pyrimidinone compounds as pde2 inhibitors

Owner:MERCK SHARP & DOHME LLC

Popular searches

Medicine Psychogenic disease Hypofunctions Psychosis Central nervous system Ganglion Striatum Aryl Isoindoline Pyrazolopyrimidine

Who we serve

R&D Engineer
R&D Manager
IP Professional

Why Eureka

Industry Leading Data Capabilities
Powerful AI technology
Patent DNA Extraction

Social media

Try Eureka

PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap